All Updates

All Updates

icon
Filter
Partnerships
FogPharma and ARTBIO partner to co-develop novel therapies for multiple cancer types
Precision Medicine
May 14, 2024
This week:
M&A
Funding
TravelPerk raises USD 135 million in debt funding for expansion; acquires AmTrav
Travel Tech
Yesterday
Product updates
Apple announces Apple Pay Later shutdown
Buy Now, Pay Later
Jun 17, 2024
Management news
Velo3D appoints Brad Kreger as permanent CEO
Additive Manufacturing
Jun 17, 2024
Partnerships
Perplexity partners with SoftBank for AI search engine promotion in Japan
Generative AI Applications
Jun 17, 2024
Product updates
Runway launches Gen-3 Alpha for generating video clips
Generative AI Applications
Jun 17, 2024
Product updates
Adobe integrates Firefly into Acrobat with chat support across multiple documents in Acrobat AI Assistant
Generative AI Applications
Jun 17, 2024
Funding
Amplify Life raises USD 20 million in Series B to expand product suite
InsurTech: Personal Lines
Jun 17, 2024
Funding
Tinybird raises USD 30 million in Series B funding to improve real-time data analytics platform
Data Infrastructure & Analytics
Jun 17, 2024
Partnerships
The EVERY Company collaborates with Grupo Palacios to develop hen-less omelets
Plant-based Dairy & Egg
Jun 17, 2024
Partnerships
Believer Meats partners with AGWA to propel cultivated meat industry in MENA region
Cell-cultured Meat
Jun 17, 2024
Precision Medicine

Precision Medicine

May 14, 2024

FogPharma and ARTBIO partner to co-develop novel therapies for multiple cancer types

Partnerships

  • Precision Oncology and biotechnology company FogPharma and radiopharmaceutical biotechnology company ARTBIO have announced a partnership to develop cancer therapies. The financial terms of the agreement have not been disclosed; however, both parties have agreed to contribute equally across all stages from research to commercialization.

  • The collaboration will leverage FogPharma’s Helicon platform's peptide capabilities and ARTBIO’s AlphaDirect platform for radioligand therapies to jointly develop Helicon-enabled ARTs (HEARTs) for multiple cancers. 

  • Massachusetts-based FogPharma is discovering and developing Helicon Therapeutics, a new class of precision medicines that can reach difficult targets. These peptides can enter cells and regulate interactions between proteins and DNA. By leveraging Helicon Therapeutics' potential, the company seeks to target intracellular mechanisms known to play pivotal roles in diseases.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.